ArticleCancer gene therapy2004
Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer.
Article in Cancer gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer.Oncotarget · 2017Article
- Enhancing radiosensitivity of TE1, TE8, and TE 11 esophageal squamous carcinoma cell lines by Hdm2-siRNA targeted gene therapy in vitro.BioImpacts : BI · 2016Article
- Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview.Cancer biology & medicine · 2014Review
- Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner.Cell division · 2014Article
- Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells.Cell death and differentiation · 2013Article
- Silence of p15 expression by RNAi enhances cisplatin resistance in hepatocellular carcinoma cells.Bosnian journal of basic medical sciences · 2012Article
- Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability.Cancer gene therapy · 2011Article
- Identification of a LNCaP-specific binding peptide using phage display.Pharmaceutical research · 2011Article
- Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation.Acta pharmacologica Sinica · 2011Article
- MITF-siRNA formulation is a safe and effective therapy for human melasma.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.Molecular pharmaceutics · 2010Article
- Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells.BMC cancer · 2010Article
- Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells.Breast cancer research : BCR · 2010Article
- Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition.Cancer gene therapy · 2009Article
- Therapeutic opportunities of small interfering RNA.Fundamental & clinical pharmacology · 2009Review
- A study on the fundamental factors determining the efficacy of siRNAs with high C/G contents.Cellular & molecular biology letters · 2008Article
- The molecular genetics of breast cancer and targeted therapy.Biologics : targets & therapy · 2007Article
- Effect of down-regulating VEGF on proliferation of colon carcinoma cell HT-29.Frontiers of biology in China : selected publications from Chinese universities · 2007Article
- RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.Gene therapy · 2006Article
- A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.Gene therapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference technology is a powerful tool for silencing endogenous or exogenous genes in mammalian cells. Here our results showed that hdm2-siRNA silenced its target mRNA specifically and effectively in human breast cancer cells, reduced tumor cell proliferation and induced apoptotic cell death. Other molecular features modified by hdm2-siRNA included decreased Bcl-2, NF-kappaB, survivin, Ras and Raf levels, elevated p53, p21, BRCA1, Bax, and caspase levels as well as altered expression of other genes. hdm2-siRNA also caused cell cycle arrest at G1 phases with reduction in cyclin and Cdk proteins. In addition, hdm2-siRNA displayed in vivo antitumor activity and increased therapeutic effectiveness of mitomycin in MCF-7 xenografts. Thus, hdm2-siRNA may be a promising gene-specific drug for the treatment of human breast cancer and other tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.